Two days after the Chief Medical Officer (CMO) confirmed T&T had registered its first case of a Vaccine-Induced Thrombotic Thrombocytopenia (VITT) on May 29 – it is possible that a second such case has occurred.
Revealing this during yesterday’s virtual media briefing hosted by the Ministry of Health, CMO Dr Roshan Parasram said confirmation of the second case was expected by last evening or for the latest, today.
Pressed to say if there had been any reports of persons developing adverse reactions to the vaccines thus far, he admitted a second case of VITT was possible.
He said, “There is a second person that we think fits the criteria that only came to light about a day ago. That is still under investigation. It seems likely that it may be another case of that syndrome. So that will be two cases of that syndrome if it is confirmed hopefully by the end of today or thereabouts.”
Parasram reported the nation’s first VITT case during last Saturday’s media briefing, as he said the patient had been administered the AstraZeneca (AZ) vaccine.
VITT has been listed as a rare side effect of the AZ vaccine.
However, the CMO further pointed to the rarity of the situation as he said it was around four in one million people that usually develop this condition.
The first patient is said to be under the care of haematologist Dr Kenneth Charles as well as their private physician; whilst the second is also carefully being monitored.
Regarding the medical conditions of the two, he said up to yesterday, “They are both well.”
These cases would have been reported to the Pan American Health Organisation (PAHO).
Indicating yesterday that some persons had developed mild allergic-type reactions 10-15 minutes after receiving their vaccine, Parasram said they had been treated and discharged.
He also reported that T&T had not recorded any vaccine-related deaths so far. (Anna-Lisa Paul)